Posts by: Vanessa Pataia

News

Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell therapy ... Read more

June 5, 2020June 5, 2020

Tislelizumab-Chemo Combo Does Well in Advanced Squamous NSCLC Trial

News

Adding Beigene‘s experimental therapy tislelizumab to standard first-line chemotherapy significantly delays disease progression or death in patients with advanced squamous non-small cell lung cancer (NSCLC), data from a Phase ... Read more

March 18, 2020April 1, 2020

FDA Approves Opdivo-Yervoy Combo for Previously Treated Liver Cancer

News

The U.S. Food and Drug Administration (FDA) approved a combination of Bristol-Myers Squibb‘s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of hepatocellular carcinoma (HCC) patients ... Read more

March 11, 2020March 11, 2020

Imfinzi, Alone or in Combo, Fails at Survival Goals in Advanced Bladder Cancer Trial

News

AstraZeneca‘s immune checkpoint inhibitor Imfinzi (durvalumab), used alone or in combination with investigational tremelimumab in Phase 3 trial in newly diagnosed people with inoperable and metastatic bladder cancer, failed to improve overall survival ... Read more

Posts by: Vanessa Pataia

Vanessa Pataia

Uppsala in Last Preclinical Stage for New CAR T-cell Product for Glioblastoma

Tislelizumab-Chemo Combo Does Well in Advanced Squamous NSCLC Trial

FDA Approves Opdivo-Yervoy Combo for Previously Treated Liver Cancer

Imfinzi, Alone or in Combo, Fails at Survival Goals in Advanced Bladder Cancer Trial

Pin It on Pinterest